Dermata, Revance Partner to Study Topical Application of Xyngari With Daxxify for Primary Axillary Hyperhidrosis
Dermata Therapeutics, Inc. and Revance Therapeutics, Inc. are partnering for a clinical trial collaboration agreement to evaluate the topical application of Xyngari (formerly known as DMT310), Dermata’s topical Spongilla powder, with daxibotulinumtoxinA-lanm (Daxxify), Revance’s botulinum toxin type A. The Companies intend to first evaluate Xyngari with for the topical treatment of primary axillary hyperhidrosis and […]